The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
List view / Grid view
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
Scientists have used nuclear magnetic resonance (NMR) spectroscopy to investigate the protein p53, which they say could advance cancer studies.
Scientists have found that Hutchinson-Gilford Progeria Syndrome (HGPS) can be prevented with treatments targeting the cardiovascular system using a novel mouse model.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
Nanobubbles known as extracellular vesicles (EVs) were shown to deliver protein drugs in animal models with inflammatory diseases.
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).